Results 21 to 30 of about 461 (125)

GLP-1 Receptor Agonists for Treating Alcohol Use Disorder: A Critical Review. [PDF]

Alcohol Clin Exp Res (Hoboken)
This narrative review of the development of GLP‐1 receptor agonists provides a foundation for both preclinical and clinical research on their use for treating alcohol use disorder (AUD). Both observational studies using real‐world data and randomized controlled clinical trials support the potential utility of these medications for treating AUD ...
Woo S, Zhu G, Castro C, Phuong A, Roy A, Davis CN, Kranzler HR.   +6 more
europepmc   +2 more sources

Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept. [PDF]

Diabetes Obes Metab
Abstract Aim Eloralintide (LY3841136) is a potent, long‐acting selective amylin receptor agonist currently under development for the treatment of obesity with once‐weekly subcutaneous dosing. Materials and Methods This 12‐week Phase 1, randomised, placebo‐controlled, participant‐ and investigator‐blinded, multiple ascending dose study evaluated the ...
Bhattachar S, Tham LS, Tidemann-Miller B, Ibriga H, Qu H, Briere DA, Haupt A, Mather KJ, Pratt E.   +8 more
europepmc   +2 more sources

Amylin as a Future Obesity Treatment

Journal of Obesity & Metabolic Syndrome, 2021
Obesity is defined as abnormal or excessive fat accumulation that contributes to detrimental health impacts. One-third of the population suffers from obesity, and it is important to consider obesity as a chronic disease requiring chronic treatment ...
Babak Dehestani, Nicholas RS Stratford, Carel W le Roux   +2 more
doaj   +1 more source

Long-acting amylin analogues for the management of obesity [PDF]

, 2022
PURPOSE OF REVIEW: To summarize recent developments of long-acting amylin analogues for the treatment of obesity and to outline their mode of action. RECENT FINDINGS: Amylin is a pancreatic hormone acting to control energy homeostasis and body weight ...
Mathiesen, David S., Jonatan I. Bagger, Bagger, Jonatan I., Knop, Filip K., David S. Mathiesen, Filip K. Knop   +5 more
core   +1 more source

Approved Anti-Obesity Medications in 2022 KSSO Guidelines and the Promise of Phase 3 Clinical Trials: Anti-Obesity Drugs in the Sky and on the Horizon

Journal of Obesity & Metabolic Syndrome, 2023
Obesity is a prevalent global health issue affecting approximately half of the world’s population. Extensive scientific research highlights the urgent need for effective obesity management to mitigate health risks and prevent complications.
Eonju Jeon, Ki Young Lee, Kyoung-Kon Kim
doaj   +1 more source

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Petrelintide for Weight Management: Two Randomized, Controlled Phase 1 Trials. [PDF]

Diabetes Obes Metab
ABSTRACT Aims Petrelintide is a long‐acting amylin analogue in development for weight management. The safety, tolerability, pharmacokinetics, and pharmacodynamics of petrelintide were evaluated in single ascending dose (SAD) and multiple ascending dose (MAD) trials. Materials and Methods Both trials were randomized, placebo‐controlled, and double‐blind.
Brændholt Olsen M, Griffin J, Hövelmann U, Macura S, Fredsted Hagen B, Hesse D, Heise T.   +6 more
europepmc   +2 more sources

Promising translatable pharmacological interventions for body weight management in individuals with severe mental illness - a narrative review [PDF]

, 2023
IntroductionPsychotropic medications, especially antipsychotics, have been consistently shown to cause weight gain in individuals with severe mental illness (SMI), a population inherently challenged by poor physical health.
Femin Prasad, Prasad, Femin, De, Riddhita, Riddhita De, Hahn, Margaret K., Filip K. Knop, Luisa Burin, Ebdrup, Bjørn H., Nicolette Stogios, Agarwal, Sri Mahavir, Stogios, Nicolette, Burin, Luisa, Margaret K. Hahn, Sri Mahavir Agarwal, Knop, Filip K., Bjørn H. Ebdrup   +15 more
core   +1 more source

An update on peptide-based therapies for type 2 diabetes and obesity [PDF]

, 2023
Long-acting analogues of the naturally occurring incretin, glucagon-like peptide-1 (GLP-1) and those modified to interact also with receptors for glucose-dependent insulinotropic polypeptide (GIP) have shown high glucose-lowering and weight-lowering ...
Flatt, Peter R, Conlon, J Michael, Bailey, Clifford J   +2 more
core   +1 more source

CagriSema drives weight loss in rats by reducing energy intake and preserving energy expenditure. [PDF]

Nat Metab
CagriSema is a combination of amylin (cagrilintide) and glucagon-like peptide-1 (semaglutide) analogues being developed for weight management. Here, we show that CagriSema blunts metabolic adaptation in rats.
Jacobsen JM, Halling JF, Blom I, Moreno Martinez J, Hald B, Pedersen K, Fels JJ, Snitker S, Secher A, Lundh S, le Roux CW, Raun K, Reitman ML, Kuhre RE.   +13 more
europepmc   +2 more sources

Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity [PDF]

, 2021
Introduction: Obesity is a growing threat to public health, increasing risks of numerous diseases and mortality, and impairing quality of life. If current trends continue, more than 1.1 billion individuals will have obesity in 2030, corresponding to ...
Jepsen, Mathies M., Christensen, Mikkel B.   +1 more
core   +1 more source